TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
Status:
Recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of TDM (therapeutic drug monitoring)-based
infliximab (CT-P13, RemsimaTM) intravenous therapy compared with the standard infliximab
(RemsimaTM) intravenous therapy for patients with active perianal fistulzing Crohn's disease.